DOCSDoximity, Inc.

Healthcare

$30.49-58% 1Y

$30.49

$18.0152 weeks$75.12

Is the price fair?

Good

Undemanding: cheap against its own history and cheap vs its sector.

2 good, 1 neutral

What the price assumes~+14% a yearderived · Jun 30, 2026

Priced for ~14% a year FCF growth. Roughly in line with its three-year revenue growth of 14% a year.

Vs its own P/E rangecheaper than 86% of its own historyderived

Cheap vs its own history: P/E 35.9 vs a 52.3 median over 21 quarters (−31% vs median).

Vs sector (EV/EBIT)15.9×derived · Mar 31, 2026

Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)behind 77% of the market

FCF yieldbehind 76% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What DOCS's price assumes

Doximity, Inc. trades at 35.9× earnings against 46.0× for the median Health Information Services name, cheaper than its own group.

35.9

Trailing P/E · Health Information Services median 46.0 · cheaper than the typical name in its group

Price / sales: 5.63
Price / sales · today's price, fiscal year to Mar 31, 2026
Free cash flow yield: 2.7%
Free cash flow yield · Health Information Services median 6.3%
Growth the price implies: +14%
Growth the price implies · The price pays for +14% free cash flow growth a year for a decade; the business has delivered −20% a year over the last three.

Details›

Price / booktoday's price, fiscal year to Mar 31, 2026: 3.82
EV / EBITtoday's price, fiscal year to Mar 31, 2026: 15.9
EV / salestoday's price, fiscal year to Mar 31, 2026: 5.29
Healthcare median P/E509 names: 26.2
Health Information Services median P/E25 names: 46.0
Free cash flow, trailing twelve months: $98M
Market capitalisation: $3.63B
3-year revenue growth: +14%
3-year free cash flow growth: −20%

What the market has paid for these earnings: 21 quarters of its own multiple × $0.85 of trailing earnings per share
Method	Per share
Its own P/E history, lower quartile	$31.77
Its own P/E history, median	$44.44
Its own P/E history, upper quartile	$51.87
52-week range	$18.01 – $75.12
Today	$30.49

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.

Health Information Services

Ranks #1 of 20 by RyuScore

Compare peers

WAY+0.76%

Waystar Holding Corp.

PRVA+3.3%

Privia Health Group, Inc.